Article

New class of antioxidants focus of Alimera Sciences, Emory agreement

Atlanta-Alimera Sciences has entered into a second exclusive worldwide agreement with Emory University to explore oxidative stress management-specifically, the reduction of reactive oxygen species (ROS)-as a treatment for ophthalmic diseases.

Atlanta-Alimera Sciences has entered into a second exclusive worldwide agreement with Emory University to explore oxidative stress management-specifically, the reduction of reactive oxygen species (ROS)-as a treatment for ophthalmic diseases.

The agreement gives Alimera the exclusive option to license a class of small-molecule compounds, known as triphenylmethanes, as a potential treatment for ocular disorders such as diabetic retinopathy and non-neovascular age-related macular degeneration, particularly geographic atrophy. This agreement follows one signed by the two parties in September that gives Alimera the option to license the nicotinamide adenine dinucleotide phosphate (NADPH) reduced form oxidase inhibitors for similar treatments.

“This second agreement with Emory expands our opportunity to develop expertise in the management of ROS and its damaging effects on the eye,” said Dan Myers, president and chief executive officer, Alimera Sciences. “Researching these compounds as well as the NADPH oxidase inhibitor compounds from our previous agreement with Emory provides Alimera with an excellent chance of addressing these significant ophthalmic disorders.”

If Alimera exercises the option in the latest agreement, the company will hold an exclusive worldwide license for the triphenylmethanes for ophthalmic indications. The agreement also grants an exclusive right to sublicense in ophthalmology and the exclusive option for non-ophthalmic use.

Alimera would be responsible for the development and commercialization of the compounds. Emory would receive milestone payments and royalties from net sales.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.